{
  "docId": "019de071-753f-7227-aa1d-36a319c59353",
  "docSlug": "7013d0966bfedd0d757b9fa24a480455",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 34,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Clinical trial design diagram showing patient flow from enrollment to treatment arms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/32",
  "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353",
  "deckJsonHref": "/decks/019de071-753f-7227-aa1d-36a319c59353.json",
  "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.75,
        "x": 0.13,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Trial flow diagram showing patient enrollment, randomization, and three treatment arms.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f82bf6dc-571a-4836-ae1f-8665f6866ba3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.78,
        "x": 0.11,
        "y": 0.66
      },
      "kind": "list",
      "text": "A planned sample size of 60 patients per arm was designed to provide acceptable precision in estimating antitumour activities in an early phase setting. Between Jan 2019 and Jul 2020, 189 patients were randomised. As of 17 May 2021, all patients had a minimum of 10 months potential follow-up.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3420c7d1-ca19-472e-8d13-c248682ba853",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.04,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "IV = intravenous; PK = pharmacokinetics.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ab32cfa-eecb-423e-9523-010bc00b25ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "A Phase II, randomised open-label trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45a36620-858d-4df8-9fa2-34532f0bd810",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Imfinzi: COAST trial design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b17921b-0164-4140-a61d-044e2694e1ad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "812b246a-4020-4c15-acb8-35c5a30c967f",
      "evidence": "Standardized representation of patient flow and treatment arms in a clinical study.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}